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Abstract
Rationale:We reported a randomized trial demonstrating daily
supplemental vitamin C to pregnant smokers significantly improved
newborn pulmonary function tests. The current study tests these
results in a new cohort using infant pulmonary function tests.
Objectives: To determine if infants of pregnant smokers
randomized to daily supplemental vitamin C would have improved
forced expiratory flows (FEFs) at 3 months of age compared with
those randomized to placebo, and to investigate the association of the
a5 nicotinic acetylcholine receptor.
Methods:A randomized, double-blind, placebo-controlled trial was
conducted at three centers. Two hundred fifty-one pregnant smokers
were randomized at 13–23 weeks of gestation: 125 randomized to
vitamin C (500 mg/d) and 126 to placebo.
Measurements and Main Results: The primary outcome was
FEF75 at 3 months of age performed with the raised volume
rapid thoracic compression technique (Jaeger/Viasys). FEF50
and FEF25–75 obtained from the same expiratory curves were
prespecified secondary outcomes. The infants of pregnant
smokers randomized to vitamin C (n = 113) had the following
FEFs at 3 months of age compared with those randomized to
placebo (n = 109) as measured by FEF75 (200.7 vs. 188.7 ml/s;
adjusted 95% confidence interval [CI] for difference, 23.33 to
35.64; P = 0.10), FEF50 (436.7 vs. 408.5 ml/s; adjusted 95% CI for
difference, 6.10–61.30; P = 0.02), and FEF25–75 (387.4 vs. 365.8
ml/s; adjusted 95% CI for difference, 0.92–55.34; P = 0.04).
Infant FEFs seemed to be negatively associated with the maternal
risk alleles for the a5 nicotinic acetylcholine receptor
(rs16969968).
Conclusions: Although the primary outcome of FEF75 was not
improved after vitamin C supplementation to pregnant smokers,
the predetermined secondary outcomes FEF50 and FEF25–75 were
significantly improved. These results extend our previous findings
and demonstrate improved airway function (FEF50 and FEF25–75) at
3 months of age in infants after vitamin C supplementation to
pregnant smokers.
Clinical trial registered with www.clinicaltrials.gov (NCT 01723696).
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Smoking during pregnancy remains a large
public health problem and is the largest
preventable cause of childhood respiratory
illness (1–3). Despite intensive smoking
cessation initiatives, more than 50% of
smokers who become pregnant continue to
smoke (4, 5). This corresponds nationwide
to at least 10% of American women
continuing to smoke when pregnant (6)
with about 450,000 exposed infants per year
at an estimated annual health care cost of
more than 1 billion dollars (7).
We previously reported a randomized
controlled trial demonstrating that giving
supplemental vitamin C (500 mg/d) to
pregnant women unable to quit smoking
significantly improved their offspring’s
newborn pulmonary function tests (PFTs)
of passive respiratory compliance and time
to peak tidal expiratory flow to expiratory
time (TPTEF:TE) measured within 72 hours
of birth (8). We also demonstrated that the
effect of maternal smoking on newborn
lung function was associated with the
maternal genotype for the a5 nicotinic
acetylcholine receptor (nAChR)
(rs16969968). This genotype is also
associated with increased risk of lung
cancer, chronic obstructive pulmonary
disease, and increased nicotine dependence
(9, 10). This trial was based on important
foundation data from a nonhuman
pregnant primate model that demonstrated
that nicotine crosses the placenta,
upregulates nicotinic receptors, and alters
lung development in the offspring with
decreased forced expiratory flows (FEFs) at
birth (11–13). In this model, vitamin C
decreased the effects of in utero nicotine on
the offspring’s FEFs (14).
Although our initial study showed
significantly improved PFTs in the
newborns of smokers allocated to vitamin C,
we did not measure FEFs because of the
instability of newborn lung volumes in the
first weeks of life and the required sedation
to perform testing. However, FEFs are a
more direct assessment of airway function,
previous studies have demonstrated
decreased FEFs in infants exposed to
maternal smoking during pregnancy
(15–18), and decreased FEFs in infancy are
correlated with increased risk of respiratory
disease (15, 16, 19). Therefore, the primary
objective of this study was to compare
the FEFs at 3 months of age in infants
of pregnant smokers randomized to
vitamin C (500 mg/d) versus placebo. We
hypothesized that the supplemental vitamin
C would improve the infant’s FEFs when
compared with placebo. Some of the results
of these studies were previously reported in
the form of an abstract (20).
Methods
Participants
Pregnant smokers were recruited from three
clinical sites: Oregon Health and Science
University (OHSU), Portland, Oregon;
Indiana University, Indianapolis, Indiana;
and PeaceHealth Southwest Washington
Medical Center, Vancouver, Washington.
This study cohort was comprised of
different patients than those recruited in our
initial trial (8). The study protocol was
approved by the three institutional review
boards. All women provided written
informed consent.
Inclusion criteria at randomization
were: women >15 years old with a
singleton gestation between 13 weeks and
0 days and 22 weeks and 6 days based on
clinical information and confirmed by
ultrasound, current cigarette smoker (>1
cigarette in last week), English-speaking,
and receiving prenatal care at surrounding
clinics to the three sites. Exclusion criteria
at randomization included: multiple
gestation, fetal anomalies, current illicit
drug use, current alcohol abuse, daily
vitamin C supplementation more than
3 days/wk (not including prenatal vitamin)
since last menstrual period, refusal to
abstain from vitamin supplements except
those from the study, history of a kidney
stone, insulin-dependent diabetes,
complex maternal medical conditions,
participation in conflicting research
projects, unable to demonstrate a stable
method of communication, pregnancy by
in vitro fertilization, plan to terminate
pregnancy, and body mass index greater
than 50 kg/m2.
Study Design and Oversight
Details of the study design were previously
published (21). We conducted a randomized,
double-blind, placebo-controlled study
of vitamin C (500 mg/d) versus placebo in
pregnant smokers.
Study staff screened women at prenatal
clinics between December 2012 and June
2015 in the catchment area of the three
clinical sites to identify eligible women who
continued to smoke cigarettes. Staff trained
in smoking cessation provided participants
with brief cessation counseling consistent
with the U.S. Public Health Service Clinical
Practice Guideline and provided a
pregnancy-specific smoking cessation
pamphlet. Smoking status and counseling
were documented in the study record (22).
On consent, women had an ultrasound for
gestational age confirmation and entered
a medication adherence trial to take
one placebo capsule/d for 7–21 days. If a
subject returned within 21 days with the
medication bottle and took at least 75% of
At a Glance Commentary
Scientific Knowledge on this
Subject: Maternal smoking during
pregnancy adversely affects lung
development with near lifelong
decreases in pulmonary function and
increased risk of wheezing, respiratory
infections, and asthma. We have
previously shown that adding daily
supplemental vitamin C for pregnant
smokers improves their infant’s
newborn pulmonary function (passive
respiratory compliance and time to
peak tidal expiratory flow to
expiratory time) measured within 72
hours of birth. We also demonstrated
that the effect of maternal smoking on
newborn lung function was associated
with the maternal genotype for the a5
nicotinic acetylcholine receptor
(rs16969968).
What This Study Adds to the
Field: This randomized trial expands
our previous study by demonstrating
increased forced expiratory flows (a
more specific measurement of airway
function) at 3 months of age in the
infants of pregnant smokers
randomized to daily vitamin C versus
placebo. The effect of maternal
smoking on infant forced expiratory
flows seemed to be increased with
maternal risk alleles for the a5
nicotinic acetylcholine receptor
genotype. Our results suggest that
vitamin C supplementation in
pregnant women who cannot quit
smoking may be a safe, inexpensive,
and simple intervention to improve
the pulmonary function of their infant
by blocking some of the effects of in
utero smoke on lung development.
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the required placebo, she proceeded to
randomization.
The vitamin C and placebomedications
were manufactured in organoleptically
identical tablets (Magno-Humphries
Laboratories Inc.) and dispensed through
the OHSU research pharmacy. Each vitamin
C tablet contained 500 mg of ascorbic acid
powder; the placebo tablet contained
microcrystalline cellulose and 100 mg of
citric acid to mimic the taste of vitamin C.
The tablets were identical in appearance,
size, and shape and dispensed in 100-tablet
quantities during the treatment period.
Participants were instructed to take one
study capsule daily, at a consistent time,
until delivery. After randomization, women
were given a standard prenatal vitamin
(Prenavite, Rugby Laboratories, 100 count)
that included 60 mg of vitamin C.
Randomization was performed at the
Data Coordinating Center using a permuted
block randomization stratified by gestational
age at time of randomization (<18 vs. .18
wk gestation) and clinical site. The OHSU
research pharmacy prepared consecutively
labeled medicine bottles to dispense, using
the randomization schedule. The study
medication was labeled with the study
identification and a consecutive study code
for the patient. The OHSU research
pharmacy dispensed the study capsules to all
sites. The investigators, clinicians, and
patients were unaware of treatment
allocation through the 3-month PFT and
remain blinded. (Consolidated Standards for
Reporting Trials diagram, Figure 1).
Study staff met with the randomized
women at each prenatal visit to collect:
interval smoking histories via a standardized
respiratory questionnaire (23), brief health
questionnaires, medication use, and
complications with review of electronic
medical records. They also provided brief
smoking cessation counseling. Adherence
with dispensed medication (vitamin C or
placebo) was assessed at each visit with pill
count by study staff and at return of each
medication bottle. Fasting maternal blood
samples for ascorbic acid levels and
maternal urine samples were obtained at
randomization, and at 26 and 32 weeks of
gestation.
Study Endpoints
The primary outcome was the comparison
of infant FEF75, the measurement of FEF at
75% of the expired volume, at 3 months of
age obtained using the raised volume rapid
thoracic compression technique in
offspring of pregnant smokers randomized
to vitamin C versus placebo. Prespecified
secondary outcomes were the FEF at 50%
expired volume (FEF50), and between 25%
and 75% expired volume (FEF25–75)
obtained from the same expiratory curve.
Forced expiratory volumes (FEV),
including FVC and FEV in the initial
0.5 seconds (FEV0.5), were obtained. Based
on findings in our prior study, in a
secondary analysis we evaluated the
potential association of the a5 nAChR
polymorphism rs16969968 (which is the a5
nAChR structural polymorphism that has
the strongest link to lung disease and
increased smoking) (9), in the effect of in
utero smoke on infant pulmonary function.
Measurements
Infant PFT at 3 months of age. Infants were
studied in the infant PFT laboratories at
Doernbecher Children’s Hospital (Oregon),
the James Whitcomb Riley Hospital
for Children (Indiana), or at Peace
Health/Southwest Medical Center
(Washington) after sedation with oral
chloral hydrate at 50–100 mg/kg. Each
site used the same PFT equipment
(Jaeger/Viasys Master Screen BabyBody).
Operational procedures were rigorously
followed across sites as outlined in the
study’s manual of operations (18, 24).
Cross-training and certification of PFT
laboratories ensured the same testing
techniques and acceptance criteria were
applied across sites. Four experienced
respiratory therapists performed all testing.
All tests were reviewed by a trained,
licensed respiratory therapist and reviewed
for acceptability, reproducibility, and
completeness. All testing was done at least
3 weeks after a respiratory illness and
analyzed testing occurred within the
predefined infant age of 10–26 weeks.
FEFs were obtained from FEF volume
curves using the raised volume rapid
thoracic compression technique with testing
performed following the American Thoracic
Society/European Respiratory Society
criteria for performance and acceptance
(24). Briefly, the lung was inflated by
applying a pressure of 30 cm H2O to the
airway with a face mask. An inflatable
jacket was used to initiate thoracic
compression at this raised volume and was
maintained until residual volume was
reached. Forced expiratory maneuvers were
repeated with increased pressure until flow
limitation was obtained. Once flow
limitation was established, the maneuver
was repeated over a 10–15 cm H2O range in
jacket pressure until three technically
acceptable curves were obtained with
FEF25–75, and FVC within 10%. The best
trial was chosen that was determined to be
the most reliable with smooth forced
expiration without evidence of early
inspiration, marked flow transients, or
glottic closure (18, 24).
Biomarkers and genotyping. Plasma
ascorbic acid measurements were performed
at the Linus Pauling Institute using high-
performance liquid chromatography with
coulometric electrochemical detection (25).
Urine cotinine levels (26) were measured
with a widely used ELISA kit following the
vendor’s protocol (Calbiotech). DNA was
prepared from ethylenediaminetetraacetic
acid whole-blood tubes using the QIAcube
and QIAamp DNA Blood Mini QIAcube
Kit (Qiagen). Mothers were genotyped
for rs16969968, which is the nAChR
polymorphism most clearly linked to
increased smoking, difficulty quitting, and
lung disease (9), by real-time PCR using
predesigned qPCR SNP genotyping
reagents (C__26000428_20) from Thermo
Fisher (Applied Biosystems). Mothers
were also genotyped for GSTM1 deletion
(Hs02575461_cn), GSTT1 deletion
(Hs00010004_cn), and GSTP1
polymorphism (C__3237198_20). All
maternal and baby DNA samples from
blood were genotyped in duplicate and any
samples that did not produce the same
result in both replicates was repeated. As
part of genotyping QC, maternal and baby
genotypes were also compared for any
mendelian violations.
Safety monitoring. All subjects were
monitored for adverse events according to
standard definition by interviewing the
subject, electronic medical record review,
and physical examination (including vital
signs monitoring during sedation). The NIH
appointed Data and Safety Monitoring
Board reviewed maternal, neonatal, and
infant adverse events every 3 months.
Statistical Analysis and Power
Our targeted sample size of 218 infants with
successful FEFs at 3 months of age was
determined to detect with 90% power, at a
significance level of 0.05, increases of 15%
in mean FEF75 in the vitamin C group
compared with the placebo group. This was
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1,225 Pregnant smokers assessed for eligibility (Screened)
333 Eligible and enrolled in placebo adherence
 run-in (Enrolled/Consented)
892 Excluded (Screen Failed)
231 Declined consent
165 Unstable method of communication or incarcerated
112 Not current smoker
95 Complex medical condition
81 Gestational age < 11.0 or >22.0 weeks
40 Not pregnant, pregnancy loss, or plans to terminate
39 Illicit drug use
36 Not receiving prenatal care at site
21 Reason not recorded
16 Multiple gestation
15 BMI > 50 kg/m2
12 Participating in another research study
9 Fetus has major congenital anomaly
6 Not English speaking
6 Moving or adoption
4 Use of additional vitamin C supplements
3 Alcohol abuse
1 In vitro fertilization
81 Excluded (Discontinued)
3 Run-in medication adherence <75%
39 Run-in medication window >21 days
4 Did not meet inclusion/exclusion criteria post ultrasound
1 Perceived drug side effects
1 Lost to follow-up
29 Withdrawal of consent
4 Fetal loss
252 Pregnant smokers randomized 1 excluded due to protocol
violation
111  Infants studied at 3-month PFT
        109 Infants with technically acceptable PFTs/FEFs
            2 Unable to obtain primary outcome  
12  Infants unavailable for 3-month PFT
      4 unable to do PFT in testing window; 1 PFT
      performed outside window; 3 withdrew consent for
      PFT; 3 lost to follow up;1 infant death
123 Infants delivered
3  Subjects terminated prior to delivery
          1 fetal loss, 2 withdrew consent
126  Randomized to receive (Placebo)
114  Infants studied at 3-month PFT
   113 Infants with technically acceptable PFTs/FEFs
           1 Unable to obtain primary outcome
6  Infants unavailable for 3-month PFT
     3 unable to do PFT in testing window; 1
        withdrew consent for PFT; 1 lost to follow
        up; 1 infant death
120  Infants delivered
5  Subjects terminated prior to delivery
           2 fetal loss, 2 withdrew consent, 1 lost to follow-up
125  Randomized to receive (Vitamin C)
Figure 1. Consolidated Standards for Reporting Trials diagram for randomized smokers. Enrollment, randomization, and follow-up of randomized
smokers and their infants through the 3-month pulmonary function tests/forced expiratory flows. BMI = body mass index; FEF = forced expiratory flow;
PFT = pulmonary function test.
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based on comparing the two means on the
log scale using 0.28 as the estimate for the
SD of FEF75 based on data in 155 healthy
infants of smoking and nonsmoking
women (27) and included allowance for 4%
of the patients to be noncompliant (took
,50% of their medications) as shown in
our initial trial (8).
Comparisons of the two treatment
groups with respect to maternal
characteristics assessed after randomization,
delivery outcomes, and non-PFT infant
characteristics at 3 months were made using
the Student’s t test for numeric variables
and the Pearson chi-square test for
categorical variables. Summary statistics of
z-scores for PFT parameters were also
calculated using the approach of Lum and
colleagues (28). The statistical analyses of
PFTs were based on intention to treat. We
analyzed FEF75, FEF50, and FEF25–75 in
infants born to mothers randomized to
vitamin C versus placebo, using analysis of
covariance general linear models. Included
in these models were treatment arm,
clinical site, and gestational age at
randomization (and all interactions of these
three factors) and the covariates of infant
sex, maternal race, and infant length at
3 months. Analyses for FVC, FEV0.5, and
FEV0.5/FVC were done using the same
analysis of covariance analyses. In
secondary analyses, a factor for the a5
nAChR (rs16969968) genotype (with levels
for major allele homozygous, heterozygous,
and minor allele homozygous) and the
interaction of genotype and treatment arm
were added to the previously mentioned
analysis of covariance models for FEF75,
FEF50, and FEF25–75.
All P values are two-sided, with
significance set at P less than 0.05.
Statistical analyses were conducted using
SAS version 9.4 (SAS Institute Inc.). The
Data and Safety Monitoring Board
reviewed results for the primary outcome
when 50% of the total sample size of
3-month PFTs were completed.
Results
Characteristics of the Trial
Participants
We screened 1,225 pregnant women who
continued to smoke in pregnancy; 892 were
excluded before consent, and 81 were
excluded after the medication adherence
period (Figure 1). We randomized
252 women; however, one subject was
subsequently identified to have met critical
exclusion criteria and therefore we analyzed
125 who received vitamin C (500 mg/d)
and 126 who received placebo (Figure 1).
Randomization balanced relevant baseline
covariates including age, race and ethnicity,
parity, and gestational age (Table 1). At
study entry, the median number of
cigarettes smoked per day in each group
was seven, and urine cotinine was
comparable in each group. Plasma ascorbic
acid levels were similar at baseline between
both groups (Table 1); at mid and late
gestation, the vitamin C group had
significantly higher ascorbic acid levels than
the placebo group (Table 2). The urine
cotinine levels were comparable between
groups at randomization, and at mid and
late gestation. Of the 243 infants at delivery,
there was no significant effect of the
intervention on delivery mode, birth
weight, gestational age, or the incidence of
prematurity (Table 2).
PFT: FEFs at 3 Months of Age
For the analysis of the primary outcome of
the 3-month FEF75, 225 infants had PFTs
attempted (92.6% of infants available at
delivery), and 222 infants (113 in the
vitamin C– and 109 in the placebo-treated
group) had successful FEFs performed
within the predetermined window of 10
through 26 weeks of infant age. After
randomization, 12 infants in the vitamin C
and 17 in the placebo group did not
complete the 3-month PFTs because of fetal
loss, infant death, consent withdrawal, loss
to follow-up, or unsuccessful sedation
(Figure 1). At the time of the attempted
3-month PFTs, infants in the vitamin C and
placebo treatment groups each had a mean
age of 15.3 weeks and length of 60.2 cm
(Table 2).
The infants born to the smokers
randomized to vitamin C had an increased
FEF75 (200.7 vs. 188.7 ml/s; adjusted 95%
confidence interval [CI] for difference,
23.33 to 35.64; P = 0.10) at 3 months of
age, and a significantly increased FEF50
(436.7 vs. 408.5 ml/s; adjusted 95% CI,
6.10–61.30; P = 0.02) and FEF25–75 (387.4
vs. 365.8 ml/s; adjusted 95% CI, 0.92–55.34;
P = 0.04) compared with those randomized
to placebo (Table 3). Regarding FEVs, there
was a significant difference in FEV0.5
Table 1. Baseline Maternal Characteristics at Randomization
Vitamin C–treated
Smokers (n = 125)
Placebo-treated
Smokers (n = 126)
Age, mean (SD), yr 26.6 (5.2) 26.4 (5.9)
White, n (%) 97 (77.6) 100 (79.4)
Gravida, median (IQR) 3.0 (2.0–4.0) 3.0 (2.0–5.0)
Gestational age, mean (SD), wk 18.4 (3.0) 18.2 (2.8)
BMI, mean (SD), kg/m2 28.6 (6.5) 30.0 (7.3)
Education status, n (%)
,High school 20 (16.0) 31 (24.6)
High school or equivalent 59 (47.2) 40 (31.7)
Some college 43 (34.4) 49 (38.9)
Bachelor’s degree 3 (2.4) 6 (4.8)
Marital status, n (%)
Married 22 (17.6) 31 (24.6)
Single 39 (31.2) 49 (38.9)
Divorced 8 (6.4) 7 (5.6)
Significant other 56 (44.8) 39 (31.0)
Health insurance, n (%)
Government assistance 112 (89.6) 106 (84.1)
Private 13 (10.4) 18 (14.3)
None or self-pay 0 (0) 2 (1.6)
Cigarettes/d, median (IQR) 7.0 (4.0–10.0) 7.5 (4.0–10.0)
Urine cotinine, median (IQR), ng/ml* 5,031 (1,885–7,058) 5,409 (1,950–8,662)
Randomization plasma ascorbic
acid, mean (SD), mmol/L†
48.7 (19.1) 49.3 (21.8)
Asthma, n (%) 44 (35.2) 38 (30.2)
History of substance abuse, n (%) 20 (16.0) 16 (12.7)
Definition of abbreviations: BMI = body mass index; IQR = interquartile range.
*Values for urine cotinine based on 121 vitamin C– and 124 placebo-treated smokers.
†Values for ascorbic acid based on 119 vitamin C– and 123 placebo-treated smokers.
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between the groups but not for FVC or
FEV0.5/FVC (Table 3).
Maternal Genotype
The addition of maternal genotype (n = 217)
for the a5 nAChR (rs16969968) into the
model of treatment and the 3-month FEFs
increased the effect size between the
treatment arms for each FEF; however, it
also increased the width of the 95% CI
(Table 4). There was no significant
interaction between maternal genotype and
treatment group. There was a significant
association of the a5 nAChR genotype in
the treatment model of vitamin C versus
placebo for FEF50, with infants of mothers
who had two copies of the risk allele for the
a5 nAChR having the lowest FEF50 in both
the vitamin C– and placebo-treated
subjects. Interestingly, the a5 nAChR
genotype seemed to have a dose–response
effect on FEF50 according to the number of
functional alleles present with vitamin C
treatment improving FEF50 compared with
placebo at each level.
Adverse Events
Adverse events were monitored. No serious
adverse events related to the intervention
were reported.
Discussion
In this randomized, double-blinded
multicenter clinical trial, infants delivered
to pregnant smokers randomized to
supplemental vitamin C (500 mg/d) did not
have a significant improvement in the
primary outcome of FEF75, but had a
significant improvement in FEF50 and
FEF25–75, which are flows obtained from the
same expiratory curve. This confirms and
expands our initial study (8) of improved
newborn PFTs with similar findings but in
a larger population with increased diversity
through the measurement of FEFs, a more
specific measurement of airway function.
We also confirm our previous findings of
the importance of the a5 nAChR in the
effect of in utero smoke on pulmonary
function.
We chose the primary outcome of
infant FEFs to build on our strong
preclinical data in nicotine exposed primates
(12, 14), and to expand our initial clinical
study of significantly improved passive
pulmonary mechanics and TPTEF:TE in
newborns of pregnant women randomized
to vitamin C versus placebo (8). Several
studies, including our own (2, 27–31), have
demonstrated that a key effect of maternal
smoking during pregnancy is a decrease in
infant FEFs, which is considered a sensitive
measurement of infant airway function. In
contrast to older children and adults,
infants have a very short rate constant for
forced expiration and the entire FVC
occurs in less than 1 second (24), therefore
some investigators use FEV0.5 to quantify
infant airway function. Among healthy
infants without previous wheezing, we
found that FEF75, FEF50, and FEF25–75, but
not FEV0.5, were lower in infants whose
mothers reported smoking during
pregnancy (27). Similarly, FEF75, FEF50,
and FEF25–75, but not FEV0.5 were better at
detecting low airway function among
infants with a history of respiratory
symptoms, but asymptomatic at the PFT
(32). Therefore, for the current study, we
chose FEF75 as our primary outcome to
assess infant airway function in the
randomized groups; however, we could
have just as easily chosen FEF50 and
FEF25–75 as the primary outcome because
they are obtained from the same expiratory
curve. The summary statistics of the
z-scores (28) of the FEFs of the vitamin
C–and placebo-treated infants (Table 5)
Table 2. Pregnancy, Delivery, and Infant Characteristics
Vitamin C
Treated
(n = 120)
Placebo
Treated
(n = 123)
Mean (95% CI)
Difference
(Vitamin C 2 Placebo)
Plasma ascorbic acid
Midgestation
Women, n 111 116
Mean (SD), mmol/L 60.8 (22.6) 41.6 (20.0)* 19.2 (13.7 to 24.8)*
Late gestation
Women, n 107 110
Mean (SD), mmol/L 54.6 (23.0) 39.6 (17.6)* 15.0 (9.7 to 20.6)
Preeclampsia/hypertension, n (%)† 8 (6.7) 13 (10.6) 3.9 (210.9 to 3.1)
Mode of delivery, n (%)
Vaginal 80 (66.7) 86 (69.9) 3.2 (214.9 to 8.4)
Cesarean 40 (33.3) 36 (29.3)
Female, n (%)† 59 (49.2) 61 (49.6) 0.4 (213.0 to 12.1)
Gestational age
Infants, n 120 123
Mean (SD), wk 38.7 (1.8) 38.6 (1.7) 0.1 (20.3 to 0.5)
Birth weight,
Infants, n 120 120
Mean (SD), g 3,123 (516) 3,078 (552) 44.6 (291.2 to 180.5)
Birth length
Infants, n 113 111
Mean (SD), cm 49.6 (3) 49.2 (3.2) 0.4 (20.4 to 1.2)
Birth head circumference
Infants, n 106 104
Mean (SD), cm 33.7 (1.9) 33.3 (2) 0.4 (20.1 to 0.9)
Delivered at ,37 wk, n (%)† 14 (11.7) 11 (8.9) 22.7 (210.4 to 4.9)
IUGR, n (%)†‡ 2 (1.7) 4 (3.3) 1.6 (22.3 to 5.5)
Infant characteristics at 3-mo PFT
Infants, n 114 111
White race, n (%)†x 89 (78.1) 88 (79.3) 1.2 (29.5 to 11.9)
Female, n (%)† 55 (48.2) 54 (48.6) 0.4 (216.7 to 13.5)
Age, mean (SD), wk 15.3 (3.2) 15.3 (3.0) 0.0 (25.6 to 5.8)
Length, mean (SD), cm 60.2 (3.2) 60.2 (2.9) 0.0 (20.8 to 0.8)
Weight, mean (SD), kg 6.4 (1.0) 6.3 (1.0) 0.1 (20.2 to 0.3)
Respiratory rate, mean (SD),
breaths/min
40 (7) 40 (7) 0.7 (21.1 to 2.5)
Definition of abbreviations: CI = confidence interval; IUGR = intrauterine growth restriction; PFT =
pulmonary function test.
*P, 0.05, ascorbic acid levels significantly different between groups at 26- and 32-wk gestation.
†Wald confidence interval.
‡Birth weight less than the 10th percentile for gestational age.
xMaternal race used as proxy for infant race.
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indicate their flows fall within normal limits
(range of mean scores from 20.38 to 0.29
for all parameters) and follow the same
general pattern/direction of the raw scores
(i.e., the z-scores of the placebo-treated
infants being lower than those of the
vitamin C–treated infants).
In this study, we confirm our previous
findings of the importance of the maternal
a5 nAChR genotype (rs16969968) in the
effect of in utero smoke on infant lung
function. This common polymorphism has
been associated with an increased risk of
lung cancer and nicotine addiction (9). In
our initial study (8), we demonstrated that
newborns of mothers who had two copies
of the a5 nAChR genotype risk allele had
the lowest measurements of TPTEF:TE and
our current study shows a similar decrease
in FEF50 in relation to the number of
functional a5 nAChR alleles, with vitamin
C improving the FEF50 at each level. This
gene environment effect may be mediated
by increased smoking, increased smoking
intensity, or by a direct effect on a5 nAChR
receptor signaling in developing lung. This
also identifies a group at particular risk of
the effects of smoking during pregnancy on
infant lung function and emphasizes the
importance of nicotine and nicotinic
signaling in mediating the effects of
maternal smoking during pregnancy.
Although this study was a randomized
placebo-controlled trial, there are several
limitations. Our study was powered to detect
a 15% vitamin C treatment effect, which we
based on our previous observation of 15%
lower FEFs among healthy infants tested at
11 months of age in which the history of
maternal smoking during pregnancy was
gathered retrospectively and not quantified
(27). We were able to demonstrate
significant increases of 7–9% in FEFs with
vitamin C treatment at 3 months of age,
showing the ability of raised volume rapid
thoracic compression maneuvers to detect
differences of this magnitude in infant
airway function. Importantly, studies have
demonstrated that decreases in FEFs in
children of mothers who smoked during
pregnancy are in this range and even
decreases of 4–6% in FEFs are associated
with increased lung disease in the children
(33). Our study was also analyzed on
intention to treat and there were about
10% of women who quit smoking after
randomization, which may have diluted our
results. Some portion of these may reflect
the effect of smoking cessation counseling
provided during the study.
Our results support the hypothesis
that oxidative mechanisms are in part
responsible for the effects of in utero
nicotine on lung development. At
randomization, both groups of pregnant
smokers had levels of fasting ascorbic acid
of 49 mmol/L that were decreased
compared with levels reported for
nonsmoking women (58 mmol/L) (34),
consistent with the increased oxidative load
associated with smoking (35). Pregnant
women randomized to the supplemental
vitamin C had significantly increased
fasting ascorbic acid levels at 26 and 32
weeks of gestation when compared with
Table 3. Pulmonary Function Tests in Infants at 3 Months of Age
Vitamin C Mean
(SD) (n = 113)
Placebo Mean
(SD) (n = 109)
Unadjusted Mean
(95% CI) Difference
(Vitamin C2Placebo)
Unadjusted
P Value
Adjusted Mean
(95% CI) Difference
(Vitamin C2Placebo)*
Adjusted
P Value*
FEF75, ml/s 200.7 (71.1) 188.7 (66.4) 12.1 (26.1 to 30.3) 0.19 16.2 (23.3 to 35.6) 0.10
FEF50, ml/s 436.7 (101.5) 408.5 (94.0) 28.1 (2.3 to 54.0) 0.033 33.7 (6.1 to 61.3) 0.02
FEF25–75, ml/s 387.4 (98.1) 365.8 (98.8) 21.6 (23.8 to 47.0) 0.096 28.1 (0.9 to 55.3) 0.04
FEV0.5, ml
† 180.0 (35.4) 173.7 (32.8) 6.3 (22.8 to 15.4) 0.17 8.6 (0.7 to 16.4) 0.03
FVC, ml 211.2 (43.7) 207.3 (43.3) 3.8 (27.7 to 15.4) 0.51 5.7 (23.7 to 15.1) 0.24
FEV0.5/FVC
† 0.80 (0.10) 0.90 (0.10) 0.01 (20.01 to 0.03) 0.18 0.01 (20.01 to 0.03) 0.20
Definition of abbreviations: CI = confidence interval; FEF25–75 = forced expiratory flow between 25% and 75% of the expired volume; FEF50 = forced
expiratory flow at 50% of the expired volume; FEF75 = forced expiratory flow at 75% of the expired volume; FEV0.5 = forced expired volume in the
initial 0.5 s.
*P values and 95% CI adjusted for design factors of site; gestational age at randomization; and covariates of length, race, and sex.
†Value not reported for one infant.
Table 4. FEF in Infants at 3 Months of Age Incorporating a5 nAChR Genotype
Vitamin C Mean
(SD) (n = 112)
Placebo Mean
(SD) (n = 105)
Adjusted Mean (95% CI)
Difference without a5
Genotype
(Vitamin C2Placebo)*
Adjusted
P Value*
Adjusted Mean (95% CI)
Difference with a5
Genotype
(Vitamin C2Placebo)*
Adjusted
P Value†
FEF75, ml/s 200.7 (70.0) 188.7 (66.3) 12.1 (26.1 to 30.3) 0.12 24.15 (20.31 to 48.61) 0.053
FEF50, ml/s 438.4 (100.2) 406.4 (94.0) 28.1 (2.3 to 54.0) 0.016 47.00 (12.8 to 81.3) 0.007
FEF25–75, ml/s 389.4 (96.3) 363.8 (93.9) 21.6 (23.8 to 47.0) 0.0493 40.00 (6.1 to 73.8) 0.021
Definition of abbreviations: a5 nAChR = a5 nicotinic acetylcholine receptor; CI = confidence interval; FEF25–75 = forced expiratory flow between 25% and
75% of the expired volume; FEF50 = forced expiratory flow at 50% of the expired volume; FEF75 = forced expiratory flow at 75% of the expired volume.
*P values and 95% CI adjusted for design factors of site; gestational age at randomization; and covariates of length, race, and sex.
†P values and 95% CI adjusted for design factors of site; gestational age at randomization; and covariates of length, race, sex, and a5 nAChR genotype.
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baseline and when compared with those
randomized to placebo. Importantly, these
levels were within the range reported
in nonsmokers (34) and demonstrate
the potential impact of nutritional
interventions to improve respiratory health
(36, 37).
Decreased pulmonary function early in
life is associated with increased respiratory
illnesses early in life, and maternal smoking
during pregnancy is a major contributor to
these adverse respiratory outcomes (38–41).
Although smoking cessation remains the
top priority, it is important to recognize the
reality that 50% of pregnant smokers will
continue to smoke despite multiple
interventions (5). Therefore, it is critical to
develop early life strategies, such as prenatal
vitamin C supplementation, to mitigate the
effects of maternal smoking to maximize
lung growth and development. Cohort
studies have found that increases in adverse
respiratory outcomes related to maternal
smoking during pregnancy track into
adulthood and may be related to
subsequent onset of chronic obstructive
pulmonary disease (42). This emphasizes
the importance of continuing to follow the
respiratory outcomes of the cohort
described here. Future trials of vitamin C
supplementation in pregnant smokers
could investigate whether a greater
treatment effect might be achieved by
earlier treatment, which would cover more
of the canalicular phase of lung
development or more prolonged vitamin C
treatment and treatment of the infant
postnatally that would cover more of lung
alveolarization (42, 43).
Although our primary outcome of
FEF75 at 3 months of age was not improved
after vitamin C supplementation to
pregnant smokers, the related measures
FEF50 and FEF25–75 obtained from the same
forced expiratory curve were significantly
improved. This extends our previous
findings of improved newborn PFTs in
infants of pregnant smokers randomized to
vitamin C versus placebo. Our findings also
suggest that vitamin C supplementation in
pregnant women who cannot quit smoking
may be a safe, inexpensive, and simple
intervention to improve their offspring’s
pulmonary function by blocking some of
the effects of in utero smoke on lung
development. These infants are in
continued follow-up to track lung function
and respiratory outcomes. n
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